CliffBio
biologic

Hemlibra

emicizumab-kxwh

Loss of exclusivityMarch 2035projected — 12-year biologic exclusivity estimate
CompanyGenentech →View the full company profile on CliffBio

Drug detail

Brand nameHemlibra
Active ingredientemicizumab-kxwh
Strength300MG/2ML (150MG/ML)
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalMarch 2023
Marketing statusRx

More from Genentech

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Hemlibra patent cliff — loss of exclusivity March 2035 | CliffBio